Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice

Monalisa Martins Trentini1, Alex Issamu Kanno1, Dunia Rodriguez1, Lazaro Moreira Marques-Neto1, Silas Fernandes Eto2,3, Ana Marisa Chudzinki-Tavassi2,3 and Luciana Cezar de Cerqueira Leite1*

1Laboratório de Desenvolvimento de Vacinas, Instituto Butantan, São Paulo, Brazil, 2Laboratory Center of Excellence in New Target Discovery (CENTD) Special Laboratory, Instituto Butantan, São Paulo, Brazil, 3Center of Innovation and Development, Laboratory of Development and Innovation, Instituto Butantan, São Paulo, Brazil

Tuberculosis (TB) is one of the deadliest infectious diseases around the world. Prevention is based on the prophylactic use of BCG vaccine, effective in infants but as protection wanes with time, adults are less protected. Additionally, chemotherapy requires the use of many antibiotics for several months to be effective. Immunotherapeutic approaches can activate the immune system, intending to assist chemotherapy of TB patients, improving its effectiveness, and reducing treatment time. In this work, the recombinant BCG expressing LTAK63 (rBCG-LTAK63) was evaluated for its immunotherapeutic potential against TB. Bacillary load, immune response, and lung inflammation were evaluated in mice infected with Mycobacterium tuberculosis (Mtb) and treated either with BCG or rBCG-LTAK63 using different routes of administration. Mice infected with Mtb and treated intranasally or intravenously with rBCG-LTAK63 showed a reduced bacillary load and lung inflammatory area when compared to the group treated with BCG. In the spleen, rBCG-LTAK63 administered intravenously induced a higher inflammatory response of CD4+ T cells. On the other hand, in the lungs there was an increased presence of CD4+IL-10+ and regulatory T cells. When combined with a short-term chemotherapy regimen, rBCG-LTAK63 administered subcutaneously or intravenously decreases the Mtb bacillary load, increases the anti-inflammatory response, and reduces tissue inflammation. These findings highlight the potential of rBCG-LTAK63 in assisting chemotherapy against Mtb.

KEYWORDS
BCG, tuberculosis, recombinant BCG, rBCG-LTAK63, immunotherapy, immunotherapeutic vaccine
Introduction

TB is a global infectious disease that affects millions of people each year. While most patients will be clinically asymptomatic and classified as latent TB, it can change to an active form under several conditions. Even with the availability of prophylactic and therapeutic treatments, TB mortality was approximately 1.5 million in 2020 (1). The chemotherapy for TB demands the administration of several antibiotics for at least 6 months, which leads several patients to abandon the treatment after a transitory recovery (1,2). Incomplete treatment contributes to the emergence of multidrug-resistant TB strains which requires an even more prolonged and complex antibiotic therapy. Although current efforts in prevention and treatment have decreased its prevalence, the situation remains far from being resolved. As a result, new strategies to treat TB patients are constantly under investigation.

The use of vaccines as immunotherapy in the treatment of TB patients is an attractive idea as it can reduce the Mtb bacillary load and result in a better clinical outcome. Immunotherapy using vaccines may be especially helpful if combined with chemotherapy (3,4). While most vaccines in clinical trials were devised as prophylactic, a limited number are also under evaluation in a post-infection immunotherapy regimen. Whole-cell vaccines are among the most advanced ones in clinical trials to which antituberculosis effect are usually associated with an increased Th1 immune response (5–11). rBCG-LTAK63 is a recombinant BCG expressing the LT toxin from Escherichia coli (12). Immunization of mice with rBCG-LTAK63 induces improved protection against Mtb challenge. Protection was associated with an increased production of Th1-related cytokines in immunized mice as well as an increase in innate and long-term immune responses (13). Interestingly, after the Mtb challenge, mice immunized with rBCG-LTAK63 showed an increased production of regulatory-related cytokines (TGF-beta and IL-10) in the lungs, resulting in considerable reduction of the inflammation associated with infection (12). We hypothesize that the therapeutic use of rBCG-LTAK63 could induce an improved control over the bacillary load and inflammation caused by Mtb infection.

In this context, we have evaluated the effect of rBCG-LTAK63 in the treatment of Mtb-infected mouse models and provide compelling evidence that it can be effective as immunotherapy for TB. Our findings also demonstrate that in a scenario where the antibiotic therapy is shorter – mimicking a discontinued chemotherapy – the immunotherapy with rBCG-LTAK63 can activate the immune system, reduce the Mtb bacillary load and the inflammation associated with the disease.

Material and methods

Animals

Six-week-old BALB/c female mice from the Biotério Central of Instituto Butantan were housed and bred in micro isolators adapted to HEPA filtered racks with 12 h light/dark cycles, temperature ranging from 20 to 22°C, and 60% humidity at the animal housing facilities of the Laboratório de Desenvolvimento de Vacinas, Instituto Butantan. This study and protocols were approved by the Ethical Committee on Animal Use of Instituto Butantan (Protocol number: 5135010819).

Mtb intranasal infection

Aliquots of Mtb (H37Rv) maintained at −80°C were thawed, and the concentration adjusted to 1.25 x 10^6 CFU/mL. Groups of 5 mice under mild anesthesia were instilled with 40 µl (500 CFU) into the nostrils with aid of a micropipette. CFU recovered from the lungs of an extra control group (with 5 animals) thirty days after infection was evaluated prior to the beginning of treatment. At this point, the CFU was 1.59 ± 0.52 x 10^6 CFU/lung (SD).

Tuberculosis immunotherapy protocols

Frozen aliquots of rBCG-LTAK63 were diluted in PBS 0.05% Tween 80 and 10^6 CFU/mouse administered through different routes. The native BCG Moreau vaccine (10^8 CFU/mouse) was administered as control. The immunotherapeutic protocol of infected animals was performed as previously described (14,15). Briefly, after four weeks of infection, the groups of BALB/c mice were treated either with one or two doses (30 days interval) of BCG or rBCG-LTAK63 administered via subcutaneous (SC, 100 µl), intranasal (IN, 40 µl), or intravenous (IV, 100 µl) routes. As control, chemotherapy with antibiotics consisting of rifampicin (RIF, 20 mg/kg) and isoniazid (INH, 50 mg/kg) (Sigma-Aldrich®, Merck KGa, St Louis, MO, USA) was given daily by gavage for four weeks. Mice were euthanized four and eight weeks after the immunotherapy, the spleen and/or lung (cranial and median lobes) collected, homogenized, diluted and plated on Middlebrook 7H10 agar (BD Difco™, Detroit, MI, USA), supplemented with 0.5% glycerol (Sigma-Aldrich®), 10% OADC (oleic acid-albumin-dextrose-catalase; BBL, Cockeysville, MD, USA), 5 µg/ml of TCH (2-thiophenecarboxylic acid hydrazide, Sigma-Aldrich®), a BCG growth inhibitor and incubated at 37°C and 5% CO2 for 2-3 weeks to verify the bacterial load as determined by the number of CFU recovered. To evaluate the combination of chemotherapy plus immunotherapy, 4 weeks after infection, RIF (20 mg/kg) and INH (50 mg/kg) were
administered by daily gavage for only 2 weeks (short-term chemotherapy). After 2 weeks interval, one dose of rBCG-LTAK63 (10^6 CFU/mouse) was administered via SC, IN or IV routes. The immune response and bacterial burden were evaluated 8 weeks after the immunotherapy.

Inflammatory immune response

Cell preparations were done as previously described (16). Briefly, mice were euthanized, and the lungs and spleens collected in ice-cold RPMI-1640 (Sigma-Aldrich®). The lungs were digested with DNase IV (30 µg/mL; Sigma-Aldrich®) and collagenase III (0.7 mg/mL; Sigma-Aldrich®) for 30–40 min at 37°C. The digested tissue was prepared as single-cell suspensions using 70 µm cell strainers (BD Pharmingen™, San Diego, CA), erythrocytes were lysed with an RBC lysis solution (150 mM NH₄Cl, 10 mM KHCO₃, pH 7.4), the cells were washed once and resuspended in RPMI-1640. Cells were counted in a Neubauer chamber using Trypan Blue and adjusted to 1 × 10⁶ cells/mL and distributed in 96-well plates (Corning®, NY, USA). The cells were stimulated with anti-CD3 (1 µg/mL, clone: OKT3, BD Pharmingen™) plus anti-CD28 (1 µg/mL, clone: CD82.2, BD Pharmingen™) for 16 h at 37°C and 5% CO₂. The supernatant was collected, and the concentration of cytokines determined by Cytometric Bead Array (BD Pharmingen™) using the Mouse Th1/Th2/Th17 Cytokine Kit.

Additionally, in order to determine the phenotype of T cells in the spleen and lungs, the samples were stained with: anti-CD4-PercP antibody (clone: RM4-5, BD Pharmingen™) and anti-CD3-APC.Cy7 antibody (clone: 17A2, BD Pharmingen™) for 30 min. Then, the cells were washed, fixed, and permeabilized using the Mouse Cytofix/Cytoperm Kit (BD). The cells were further incubated for 30 min with anti-TNF-α-PE (clone: MP6-XT2, BD Pharmingen™), anti-IFN-γ-APC (clone: XMG1.2, BD Pharmingen™), anti-IL-17-BV421 (clone: TC11-18H10, BD Pharmingen™), and anti-IL-10-PE.Cy7 (clone: JESS-16E3, BD Pharmingen™). Splen and lung cells were also evaluated for their T regulatory phenotype by staining with Mouse Th17/Treg Phenotyping Kit (BD Pharmingen™). The cells were incubated with anti-CD4-PercP antibody (clone: RM4-5) and anti-CD25-PE antibody (clone: PC619) (BD Pharmingen™) for 30 min. Then, the cells were washed, fixed, and permeabilized using the Mouse Foxp3 Cytofix/Cytoperm Kit (BD). The cells were further incubated for 50 min with anti-Foxp3-AlexaFluor647 antibody (clone: MF23, BD Pharmingen™). Data were acquired on a FACSComp II flow cytometer (BD Pharmingen™) and analyzed using the FlowJo 8.7 software.

Immunopathological evaluation of the lungs

After infection and treatments, the right caudal lung lobes of mice were collected and fixed in 10% paraformaldehyde (Labsynth®, Diadema, SP). Fixed tissues (5 µm thick) were placed onto glass slides and stained with hematoxylin and eosin (H&E). The intensity of lung inflammation was evaluated according to (17). In brief, H&E-stained sections were photographed at 40 x magnification using a microscope (Axio Imager M2 Zeiss) coupled to a digital camera (AxioCam MRm Zeiss). Image analysis software (ImageJ, National Institutes of Health, USA) was used to determine the pulmonary area affected. Briefly, five images at 40 x magnification per lung lobule, totaling 25 images per group, were randomly selected, and analyzed for the qualitative evaluation of the cell infiltrate and intra-alveolar regions (17–19). To measure the areas of interest, the images were transformed into 8-bit and treated with threshold and percentage of the measured area. For leukocyte counting, the Color Deconvolution 2 plugin was used to visualize and separate nuclei from the cytoplasm. For cell counting, the Cell Counter plugin was used. This analysis is used to facilitate the differential counting of segmented and mononuclear nuclei.

Statistical analysis

The data were imported to Excel (version 14.3.4, 2011) and analyzed using Graphpad Prism Software 6.0. Statistical analysis was performed by one-way ANOVA followed by Bonferroni test; p values < 0.05 was considered statistically significant. Values are reported as the mean ± SD.

Results

rBCG-LTAK63 immunotherapy reduces Mtb bacillary load

To determine the immunotherapeutic potential of rBCG-LTAK63, BALB/c mice were infected with Mtb and treated with a single dose of BCG or rBCG-LTAK63 administered via the SC, IN, or IV routes after 4 weeks of infection. The infection of Mtb was performed using the intranasal route with 500 CFU/mouse to mimic the natural infection route, as previously described (20) (Supplementary Figure 1). Four weeks after treatment with rBCG-LTAK63, either by the IN or IV routes, showed significantly reduced bacillary load (Figures 1A, C). Furthermore, the treatments also induced reduced bacterial load in the spleens (Supplementary Figure 2). The complete chemotherapy with INH (50 mg/kg) and RIF (20 mg/kg) administered daily by gavage for 4 weeks was used as positive control. Neither BCG treatment by any route nor rBCG-LTAK63 administered SC were able to reduce the bacillary load (Figure 1B). Additionally, we investigated whether this reduction would persist for longer periods after the treatment. At eight weeks after treatment the immunotherapy with rBCG-
LTAK63 via IN or IV also showed a reduced *Mtb* bacillary load (Figures 1C, D). Again, neither rBCG-LTAK63 administered SC nor BCG by any route showed reduction in bacillary load. Comparison of rBCG-LTAK63 administered by different routes demonstrate that the IV route resulted in a greater reduction in the bacillary load than the IN route (Figures 1B, D). On the other hand, two doses of rBCG-LTAK63 did not show therapeutic effectiveness in any administration route (IV, IN, or SC) (Supplementary Figure 3).

Notably, the group treated with antibiotics exhibited reduced effectiveness over time, which is not observed in the rBCG-LTAK63 vaccine-treated group; that is, in the lungs of animals treated with antibiotics, there is a small increase in bacillary load with time that is not observed in the group treated with rBCG-LTAK63 (Supplementary Figure 3).

To evaluate the degree of inflammation, the lungs of infected mice treated with BCG or rBCG-LTAK63 were processed for histopathological examination. Mice infected with *Mtb* (Infection group) developed widespread and diffuse pneumonia, as well as an inflammatory infiltrate surrounding the blood vessels and airways (Figure 2A). In comparison, mice treated with the BCG vaccine (IN and IV routes) developed pneumonia patches and had more severe perivascular and peribronchiolar inflammatory infiltrates than animals treated with rBCG-LTAK63 or conventional antibiotics (RIF/INH) (Figure 2A). Surprisingly, mice treated rBCG-LTAK63 (IN and IV routes) showed decreased lung inflammation (Figure 2B) with reduced neutrophils, macrophages and lymphocytes efflux when compared with the infected animals or mice that received BCG (Figures 2C–E).

rBCG-LTAK63 therapy modulates the inflammatory response induced by *Mtb*

Since the immunotherapy with rBCG-LTAK63 decreased bacillary load and the cellular infiltrate in the lungs of *Mtb-*
infected mice, we evaluated the profile of inflammatory and regulatory CD4+ T cells in the lungs and spleens following the IN or IV treatment with rBCG-LTAK63 (the gating strategy is shown in Supplementary Figure 5). Four and eight weeks after treatment, the mice that received rBCG-LTAK63 IV showed an increased presence of splenic CD4+ IL-17+ (Figure 3A) and CD4+ TNF-α+ (Figure 3B). The increase of CD4+ IFN-γ+ in the spleen was not statistically significant (Figure 3C). At the same time, a reduced presence of these cells was observed in the lungs. This was observed at four (Figures 3F–H) and eight weeks after...
treatment (Figures 3L, M), as determined by IL-17 (Figures 3F, I), TNF-α (Figures 3G, K) and IFN-γ (Figures 3H, M) CD4+ T cells. Interestingly, the lower inflammatory response in the lungs from the rBCG-LTAK63 IV treatment was accompanied by an increased number of regulatory T cells (CD4+CD25+FoxP3+) in the spleen and lungs (Figures 3E, J, O). Furthermore, increased CD4+IL-10+ was observed in the lungs in comparison to the Infection group (Figures 3D, I, N). These findings show that the IV treatment with rBCG-LTAK63 increases the inflammatory response in the spleen and decreases inflammation in the lungs, which may be correlated with the increase in regulatory T cell response.

When two doses of rBCG-LTAK63 were administered the main effect observed was in IL-17 production through the IN and IV routes. Additionally, the IN route showed a significant increase in IFN-γ produced by lung cells (Supplementary Figure 6). The lung mucosal route will induce mostly IL-17, due to the Lung associated Lymphoid Tissue which produces more IL-6 and TGF-b.

Association of chemotherapy and immunotherapy with rBCG-LTAK63

The antibiotic therapy for TB can last several months and is one of the most common reasons for its discontinuation. After showing that rBCG-LTAK63 may be effective in reducing bacillary load and lung inflammation associated with the infection, we tested whether its combination with a reduced regimen of antibiotic therapy could improve the resolution of the infection (e.g., lower bacillary loads and/or disease-related inflammation).

To test this hypothesis, antibiotics were administered for only 2 weeks (half treatment) and two weeks after the end of chemotherapy, they received a single dose of rBCG-LTAK63 (SC, IN or IV route) (Figure 4A). Bacillary load in the spleen (Figure 4B) and lungs (Figure 4C) was determined 8 weeks later. As expected, the reduced chemotherapy decreased the bacillary load (~1.5 log10 reduction), but less efficiently than the full 4 weeks regimen (~3 log10 reduction). As hypothesized, the combination of antibiotic and immunotherapy with rBCG-LTAK63 (SC and IV routes) exhibited a substantial decrease in bacillary load in the spleen and lungs, as compared to the group that received only antibiotics (Figures 4B, C). Surprisingly, chemotherapy plus rBCG-LTAK63 administered via the IN route did not show any further reduction in comparison to chemotherapy only.

The immune response assessed by the production of inflammatory cytokines by spleen cells from these groups revealed higher levels of TNF-α when rBCG-LTAK63 was delivered by any route, higher IFN-γ when SC and IV was used and higher IL-17 through SC delivery (Figures 5A, C, E). In lung cells, a decrease in the production of these cytokines was observed especially when rBCG-LTAK63 was administered via SC and IV (Figures 5B, D, F). Interestingly, one combination (antibiotics and rBCG-LTAK63 SC route) induced an increase in the number of regulatory T cells in both the spleen and lungs (Figures 5G, H). The intravenously treated group also exhibited an increase in the number of regulatory T cells in the lungs. Accordingly, the lungs of these animals (chemotherapy plus rBCG-LTAK63 SC or IN route) showed reduced pneumonia and had fewer perivascular and peribronchiolar inflammatory infiltrates when compared to the Infection group or to the group treated with antibiotics (half regimen) (Figure 6A). Moreover, the cellular infiltrate was less prominent as demonstrated by the reduced lung inflammatory area (Figure 6B). The shorter chemotherapy regimen plus rBCG-LTAK63 (all 3 routes) induced lower inflammatory area also in comparison to the antibiotic group. Moreover, different routes of administration appear to recruit distinct numbers of neutrophils, macrophages, and lymphocytes. rBCG-LTAK63 administered IV resulted in higher number of neutrophils and macrophages in comparison to SC (Figures 6C, D). On the other hand, the number of lymphocytes was higher in the IN group in comparison to SC (Figure 6E). These results suggest that the immunotherapy with rBCG-LTAK63 can complement a reduced regimen of chemotherapy resulting in lower bacillary loads and lung inflammation.

Discussion

In this study, we showed the immunotherapeutic potential of rBCG-LTAK63 in a Mtb-infected murine model. rBCG-LTAK63 induces an inflammatory response in the spleens combined with a regulatory response in the lungs, and results in reduced bacillary loads. A second dose of rBCG-LTAK63 increased the immune response but did not reduce bacterial burden. This result is expected since most live vaccines are administered in only one dose due to persistence in the organism. BCG is not effective, probably due to the previous presence of Mtb before treatment. The differential effect seen with rBCG-LTAK63 could be due to the adjuvant effects of the toxin derivative.

The immunotherapy with rBCG-LTAK63 can be further combined with conventional antibiotics aiming at reducing the time of chemotherapy required. Other immunotherapeutic strategies commonly used include vaccines in association with chemotherapy (5–7, 21–23). Importantly, these candidates demonstrate increased Th1 responses also as prophylactic vaccines (24–26). The M. vaccae, RUTI, MIP and VPM1002 are candidates in clinical trials as prophylactic and therapeutic vaccines. They can activate the Th1-related immune response and work in synergy with antibiotics to reduce the bacterial burden. A common feature in these vaccines is the requirement of two or more doses to control the Mtb infection.

In our studies, we did not combine immunotherapy and chemotherapy at the same time. Since rBCG-LTAK63 is a live vaccine, this feature is important for the protection obtained and concomitant use of antibiotics could compromise its efficacy.
Immunotherapy with rBCG-LTAK63 modulates proinflammatory and regulatory immune responses in Mtb-infected mice. BALB/c mice were infected with Mtb (Infection) and treated with RIF/INH (via gavage for 4 weeks) or a single dose of rBCG-LTAK63 delivered intranasally (IN) or intravenously (IV). The immune response in the spleen and lungs was evaluated four and eight weeks post-treatment (4wpt and 8wpt). The number of CD4^+ T cells producing IL-17, TNF-α, IFN-γ and IL-10 in these organs was determined by staining with mouse monoclonal antibodies anti-CD4-APC.CY7, anti-CD3-APC.CY7, anti-CD4-PercP and anti-IL17-BV421, anti-TNF-PE, anti-IFN-APC or anti-IL-10-PE.Cy7. The percentage regulatory T cells was determined by staining with mouse monoclonal antibodies anti-CD4-PercP and anti-CD25-PE and anti-FoxP3-APC, and analyzed using Flow Cytometer FACS Canto II and FlowJo 8.7 software. Statistical differences were determined by one-way ANOVA with a Bonferroni test. *p values ≤ 0.05 were considered statistically significant. Asterisks over the columns refer to the comparison with the infection group. Results are represented by the means ± SD of the percentage of CD4^+ T cells (for IL-17, TNF-α, IFN-γ and IL-10) or the percentage of regulatory T cells in the CD4^+ population (n=5/group).
Striking differences of live and killed BCG have been reported (27, 28). Here, after a shorter use of conventional antibiotics, a single dose of rBCG-LTAK63 was administered. Through this approach, an additional reduction in Mtb bacillary load was observed suggesting that this scheme may compensate treatment abandonment; the long time required to cure a patient is regarded as one of the major obstacles to the success of TB treatment (29, 30). This may be especially important since the immunotherapy alone with rBCG-LTAK63 prevented the expansion of Mtb bacillary load. When only the antibiotic was used, there was an increase in CFU after cessation of treatment. On the other hand, rBCG-LTAK63 maintained the CFU stable for at least 8 weeks after treatment. This is probably related to its activity on the immune system cells that will continue to act even if the treatment is interrupted, while the antibiotic needs a minimum concentration (bioavailability) to maintain its therapeutic effect. Further investigation will determine whether the vaccine can impair the replication of Mtb for a longer time.

The immunotherapy with rBCG-LTAK63 resulted in a considerable increase of pro-inflammatory cytokines, such as TNF-α, IL-17 and IFN-γ, in the spleens. On the other hand, there was a decrease of these in the lungs. Immunotherapy of TB is based on the induction of immune activity and suppression of immune responses, e.g., excessive inflammation, which otherwise may cause tissue damage (31). When vitamin D (1α, 25-dihydroxy-vitamin D3) is administered in the immunotherapy of TB, there is a regulation of the pro-inflammatory response associated with bacterial clearance and decrease of pathological lesions in the lungs (32, 33). Anti-inflammatory cytokines, such as IL-10 and TGF-β counteract pro-inflammatory-mediated effects. Interestingly, we observed an increased number of the regulatory T cells and CD4+IL-10+ in the lungs of mice treated IV with rBCG-LTAK63. Coincidently, as a prophylactic vaccine, the immunization with rBCG-LTAK63 also induces an increase in IL-10 and TGF-β in the lungs of mice after Mtb challenge (12). Furthermore, a balance of pro and anti-inflammatory responses is associated with the differentiation of T helper subsets during the Mtb infection and with disease outcome (34, 35).

Our findings demonstrate that immunotherapy with rBCG-LTAK63 reduces both bacterial burden and pathology in the lungs when administered via parenteral (IV) or respiratory routes (IN), while the combination with chemotherapy was effective when administered SC or IV. Several studies reported that parenteral immunotherapies or immunizations fail to control TB, a fact related to poorly induced Ag-specific T cells in the lungs (36, 37). This indicates that Ag-specific immune responses may be induced by either route of administration with rBCG-LTAK63. Accordingly,
FIGURE 5
Reduced chemotherapy in combination with rBCG-LTAK63 modulates the immune response in the spleen and lungs of Mtb-infected mice. BALB/c mice were infected with Mtb (500 CFU/IN) and treated 4 weeks later with rifampicin and isoniazid (RIF/INH) for 2 weeks. After two weeks interval, rBCG-LTAK63 treatment was administered via SC, IN or IV routes. Eight weeks after treatment, spleens and lungs were recovered, and the number of CD4+ T cells producing IL-17 (A, B), TNF-α (C, D) and IFN-γ (E, F) in these organs was determined by staining with mouse monoclonal antibodies antiCD3–APC.CY7, anti-CD4–PercP and anti-IL17–BV421, anti-TNF–PE, anti-IFN–APC. Regulatory T cells (G–H) were stained using mouse monoclonal antibodies anti-CD4–PercP, anti-CD25–PE and anti-FoxP3–APC, and analyzed using Flow Cytometer FACS Canto II and FlowJo 8.7 software. Statistical differences were determined by one-way ANOVA with a Bonferroni test. * p values ≤ 0.05 were considered statistically significant. Asterisks over the columns refer to the comparison with the infection group. Results are represented by the means ± SD (n=5/group).
previous studies have shown a high number of Ag-specific T cells in the spleen and lungs of rBCG-LTAK63-immunized mice (12, 13).

In our results, the sole use of rBCG-LTAK63 through the IN and IV routes (without chemotherapy) was more efficient in reducing the TB burden than SC. It’s known that immune responses are compartmentalized and the IN administrations may benefit from direct stimulation of local immune response, while IV would benefit from its faster (IV facilitating delivery to several organs including the lungs) and stronger stimulation (inducing systemic and local immune responses). On the other hand, although the SC route will induce systemic responses, the priming process is slower when compared to the IV route (38).
When we combined immunotherapy and chemotherapy, IV and SC, but not IN, reduced even further the bacterial load. Our data showed that the immune response (IL-17, TNF-α, and IFN-γ) in the lungs directly correlates with the Mtb load, while in the spleens it correlates better with the immunotherapy. This divergence may be due to the chemotherapy effect, which boosts systemic T cell responses (as dead bacilli may be processed and properly presented to lymphocytes) and may explain why systemic immunotherapy works better than the local approach.

Severe TB pathology is associated with the uncontrolled secretion of pro-inflammatory cytokines and chemokines, extensive neutrophilic infiltration, and intensified T cell responses, especially Th1 responses (39, 40). In this study, we demonstrated that immunotherapy with rBCG-LTAK63 results in neutrophil eflux control with smaller inflammatory foci mainly constituted by mononuclear/lymphocytic cells. This may be important in reducing tissue damage, enabling enough influx to generate a lymphocytic-enriched granuloma and could reduce intracellular Mtb niches in the lungs (41, 42). Here we show that rBCG-LTAK63 immunotherapy induced a timely modulation of the pro and anti-inflammatory responses and was effective in reducing Mtb bacillary loads. Although histology highlights the effect of treatment in the control of inflammation/pathology by rBCG-LTAK63, it is not possible to identify cell subsets. Future studies (with more specific techniques such as immunohistochemistry of flow cytometry) can further clarify the specific mechanism by which rBCG-LTAK63 decreases the progression of TB pathogenesis, and whether immunotherapy with rBCG-LTAK63 would also be effective in previously immunized recipients or those exposed to environmental mycobacteria. Ultimately, immunotherapy can be combined with conventional antibiotics being especially relevant to tackle non-adherence to conventional chemotherapy.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Author contributions

MT, DR, AK and LL conceived and designed the experiments; MT, LM-N and SE performed the experiments and collected data; MT, LM-N, DR, AK, SE, AC-T and LL processed and analyzed the data; MT, LM-N, DR, AK, SE and LL wrote the manuscript, and all authors critically revised the manuscript. All authors contributed to the article and approved the submitted version.

Funding

We acknowledge the support from FAPESP (Projects 2017/24832-6, 2019/06454-0 and 2019/02305-0) and Fundação Butantan.

Conflict of interest

LL has a patent application on the use of rBCG-LTAK63 as vaccine against Mtb.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.943558/full#supplementary-material
Trentini et al. 10.3389/fimmu.2022.943558

References

1. World Health O. Global tuberculosis report 2021. Geneva: World Health Organization (2021).
2. Tiberi S, du Plessis N, Wald G, Vjeka MJ, Rao M, Ntomu F, et al. Tuberculosis: Progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis (2018) 18:e183–98. doi: 10.1016/S1473-3099(18)30110-5
3. Sable SB, Posey JE, Sriza T. Tuberculosis vaccine development: Progress in clinical evaluation. Clin Microbiol Rev (2022) 35:e00100–19. doi: 10.1128/CMB.00100-19
4. Gong W, Liang Y, Wu X. The current status, challenges, and future developments of new tuberculosis vaccines. Hum Vaccin Immunother (2018) 14:1697–716. doi: 10.1080/21645515.2018.1458806
5. Stanford JL, Bahr GM, Rook GA, Shaaban MA, Chught AD, Gabriel M, et al. Immunotherapy with mycobacterium vaccae as an adjunct to chemotherapy in the treatment of pulmonary tuberculosis. Tubercle (1996) 77:81–93. doi: 10.1016/S0041-3879(96)80022-P
6. Cardona P-J. RUTI: A new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis (2006) 86:273–89. doi: 10.1016/j.tube.2006.05.005
7. Gupta A, Ahmad FJ, Ahmad F, Gupta UD, Natarajan M, Katoch V, et al. Efficacy of mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses as in the lungs. PLoS One (2012) 7:e29225. doi: 10.1371/journal.pone.0029125
8. Coler RN, Bertholet S, Pine SO, Orr MT, Reese V, Windish HP, et al. Therapeutic immunization against mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis (2013) 207:1242–52. doi: 10.1093/infdis/jjt425
9. NeB AS, D’loum E, Bouc P, Sabate M, Bosser R, Picacs J, et al. Safety, tolerability, and immunogenicity of the novel antibacterial vaccine RUTI- Randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One (2014) 9:e89612. doi: 10.1371/journal.pone.0089612
10. Huang CY, Hsieh WY. Efficacy of mycobacterium vaccae vaccine immunotherapy for patients with tuberculosis: A systematic review and meta-analysis. Hum Vaccines Immunother (2013) 16:1960–71. doi: 10.1089/avim.2012.0160
11. Santhiago IP, D’Souza SS, Nagarajan D, Narayanan GM, Ramamurthy P, et al. Tuberculosis reprogramming of CD4 T cell homing into the lung. Microbiol Immunol (2017) 61:238–47. doi: 10.1111/mi.12694
12. Carvalho Dos Santos C, Rodriguez D, Kanno Issam A, Cezar De Cerequeira Leite L, Pereira Nascimento I. Reombinant BCG expressing the LTAK63 adjuvant induces superior protection against mycobacterium tuberculosis. Sci Rep (2017) 7:2109. doi: 10.1038/s41598-017-02003-9
13. Rodrigues RF, Zaraté-Blades CR, Rios WM, Soares LS, Souza PRM, Brandão JT, et al. Synergy of chemotherapy and immunotherapy revealed by a genome-scale analysis of murine tuberculosis. J Antimicrob Chemother (2014) 70:1774–83. doi: 10.1093/jac/dkt203
14. Liang Y, Zhao Y, Bai X, Xiao L, Yang L, Zhang J, et al. Immunotherapeutic effects of mycobacterium tuberculosis rv3407 DNA vaccine in mice. Autoimmunity (2018) 51:417–22. doi: 10.1080/08940393.2018.1546291
15. Trentini MM, de Oliveira FM, Kipnis A, Junqueira-Kipnis AP. The role of mycobacterium tuberculosis in the introduction of immunotherapy with mycobacterium vaccae into the routine treatment of TB. Immunother (2013) 6:357–68. doi: 10.2217/imt.13.116
16. Skinner MA, Yuan S, Preidtige R, Chok D, Watson JD, Tan PL. Immunization with heat-killed mycobacterium vaccae stimulates CD8+ cytotoxic T cells specific for macrophages infected with mycobacterium tuberculosis. Infect Immun (1997) 65:4525–30. doi: 10.1128/iai.65.12.4525-4530.1997
17. Das S, Chowdhury BP, Gowsami A, Parteen S, Jawed J, Pal N, et al. Mycobacterium indicus pranii (MIP) mediated host protective intracellular mechanisms against tuberculosis infection: Involvement of TLR-4 mediated signaling. Tuberculosis (2016) 101:201–9. doi: 10.1016/j.tube.2016.09.027
18. Gengenbacher M, Niewenhuizen N, Vogelzang A, Liu H, Kaiser P, Schauer S, et al. Deletion of nuoG from the vaccine candidate mycobacterium bovis BCG AureC:ily improves protection against tuberculosis. MBio (2016) 7:e00879–16. doi: 10.1128/mBio.00879-16
19. Haile M, Schröder U, Hamasur B, Pawloski A, Jazmär T, Kallemius G, et al. Immunization with heat-killed mycobacterium bovis bacille calmette-guérin (BCG) in Europe1 LM3 adjuant protects against tuberculosis. Vaccine (2004) 22:1498–508. doi: 10.1016/j.vaccine.2003.10.016
20. Whelan AO, Wright DC, Chambers MA, Singh M, Hewinson RG, Vordermeier HM. Evidence for enhanced central memory priming by live mycobacterium bovis BCG vaccine in comparison with killed BCG formulations. Vaccine (2008) 26:166–73. doi: 10.1016/j.vaccine.2007.11.005
21. Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev (2015) 2015(5):CD003343. doi: 10.1002/14651858.CD003343.pub4
22. Munro SA, Lewin SA, Smith HI, Engel ME, Freethin A, Volmink J. Patient adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS Med (2007) 4:1240–5. doi: 10.1371/journal.pmed.0040238
23. Doherty TM. Immunotherapy for TB. Immunotherapy (2012) 4:629–47. doi: 10.2217/imt.12.52
24. Coussens LA, Timms BM, Boucher BJ, Venton TR, Ashcroft AT, Skolimowska KH, et al. 16S, 25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by mycobacterium tuberculosis infection. J Infect Dis (2009) 177:539–48. doi: 10.1086/594832
25. Kololfi A, Subbian S. Host-directed therapeutic strategies for tuberculosis. Front Med (2017) 4:1. doi: 10.3389/fmed.2017.00017
26. Kumar R, Singh P, Kololfi A, Shi L, Bushkin Y, Tyagi S, et al. Immunomodulation of phagocytes during mycobacterium tuberculosis infection. Front Immunol (2016) 7:48. doi: 10.3389/fin.2016.00049
27. Jeyanathan M, Yao Y, Athamini S, Small F, Xing Z. New tuberculosis vaccine strategies: Targeting at un-natural immunity. Trends Immunol (2018) 39:419–33. doi: 10.1016/j.ti.2018.01.006
28. Beverley PCL, Ruzics Z, Hey A, Hutchings C, Boos S, Bollinger B, et al. A novel murine cytomegalovirus vaccine vector protects against mycobacterium tuberculosis. J Immunol (2014) 193:2306–16. doi: 10.4049/jimmunol.1302523
29. Power CA, Wei G, Breschet PA. Myobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect Immun (1998) 66(12):5741–50. doi: 10.1128/IAI.66.12.5741-5750.1998
30. Lyadova IV. Neutrophils in tuberculosis: Heterogeneity shapes the way? Mediators Inflamm (2017) 2017:2651970. doi: 10.1155/2017/2651970
31. Lyadova IV, Navasov KS, Zapata LM, Larralde D, Radaeva TV, et al. In mice, tuberculosis progression is associated with intensive inflammatory response and the accumulation of gr-1dim cells in the lungs. PLoS One (2015) 10(6):e010469. doi: 10.1371/journal.pone.010469
32. Sá JK, Rengarajan J. Immunology of mycobacterium tuberculosis infections. Microbiol Spectr (2019) 7(1). doi: 10.1128/microbiolspec.GPS-0002-2018
33. Ehlers S, Schaub U. The granuloma in tuberculosis: Dynamics of a host–pathogen collusion. Front Immunol (2013) 3:411. doi: 10.3389/fimmu.2012.00411